Brenntag and Budenheim partner on BYPHAR biopharma phosphates
- Brenntag and Budenheim form a strategic partnership to supply biopharma-grade phosphates under Brenntag’s BYPHAR channel.
- Co-branded Budenheim phosphates will be sold globally in pack sizes of 15 kg or less via BYPHAR; Budenheim’s PharSQ Pure will be distributed by Brenntag in 25 kg+ packaging across Europe.
- Portfolio comprises seven GMP-manufactured phosphates: monosodium phosphate (anhydrous/monohydrate/dihydrate) and disodium phosphate (anhydrous/dihydrate/heptahydrate/dodecahydrate).
- Products are monograph-compliant, microbiologically controlled and endotoxin tested for uses including buffer preparation, cell culture, downstream processing and formulation.
Partnership scope
Brenntag announced a strategic collaboration with Budenheim to combine Budenheim’s high-purity phosphate manufacturing with Brenntag’s biopharma services and distribution. The tie-up aims to serve customers needing both commercial-scale supply and smaller, biopharma-oriented pack sizes.
Packaging and distribution
Budenheim’s dedicated biopharma phosphates will be offered through Brenntag’s BYPHAR brand in pack sizes of 15 kg or less, available globally to support development through commercial manufacturing. Budenheim’s PharSQ Pure line will continue in packaging of 25 kg and above and will be distributed by Brenntag solely across Europe.
Products and applications
The portfolio includes seven GMP-manufactured phosphates (monosodium phosphate: anhydrous, monohydrate, dihydrate; disodium phosphate: anhydrous, dihydrate, heptahydrate, dodecahydrate). These products are monograph-compliant, microbiologically controlled and endotoxin tested, targeting buffer preparation, cell culture, downstream processing and formulation.
Source: Brenntag
